Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 3/20 | 0.64 |
| ▸ | TTBK2 | Q6IQ55 | 3/20 | 0.64 |
| ▸ | EGFR | P00533 | 12/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.60 |
| ▸ | ERBB3 | P21860 | 8/20 | 0.60 |
| ▸ | ERBB4 | Q15303 | 8/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 2/20 | 0.56 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.54 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16432121 | 0.83 | EGFR (0.71) | TTBK1TTBK2EGFRERBB2ERBB3 | |
| SCHEMBL4544706 | 0.80 | EGFR (0.60) | TTBK1TTBK2EGFRERBB2ERBB3 | |
| SCHEMBL2253412 | 0.80 | EGFR (0.61) | EGFRMAPTHTTMEN1KMT2A | |
| SCHEMBL4913787 | 0.77 | RAB9A (0.72) | TTBK1TTBK2MAPTNPC1RAB9A | |
| SCHEMBL24881479 | 0.75 | TTBK1 (1.00) | TTBK1TTBK2 | |
| SCHEMBL2748830 | 0.74 | ERBB2 (1.00) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL2748898 | 0.74 | EGFR (0.61) | EGFRERBB2ERBB3ERBB4MAPT | |
| SCHEMBL3401165 | 0.74 | NPC1 (0.97) | EGFRERBB2ERBB4MAPTGRM1 | |
| SCHEMBL3339302 | 0.74 | MAPT (1.00) | EGFRERBB2MAPTGRM1NPC1 | |
| SCHEMBL18963653 | 0.73 | DYRK1A (0.53) | EGFRERBB2ERBB3ERBB4PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993634-B2 | Methods and use of compounds that bind to Her2/neu receptor complex | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-03-31 | — | — | US | disclosed |
| EP-1752457-B1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-20130190405-A1 | METHODS AND USE OF COMPOUNDS THAT BIND TO HER2/NEU RECEPTOR COMPLEX | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-07-25 | — | — | US | disclosed |
| US-8178543-B2 | growth factor receptor tyrosine kinase inhibitor; anticarcinogenic agents; N-{2-[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-3-hydroxy-3-methylbutanamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178543-B2 | growth factor receptor tyrosine kinase inhibitor; anticarcinogenic agents; N-{2-[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-3-hydroxy-3-methylbutanamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| WO-2011153050-A1 | METHODS AND USE OF COMPOUNDS THAT BIND TO HER2/NEU RECEPTOR COMPLEX | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-12-08 | — | — | WO | disclosed |
| EP-2359825-A2 | Combination drug | Takeda Pharmaceutical Company Limited (JP) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011040212-A1 | THERAPEUTIC AGENT FOR BRAIN TUMOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-07 | — | — | WO | disclosed |
| US-20110003805-A1 | CONCOMITANT DRUG | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2253633-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-20090029973-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090029973-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090018335-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20090018335-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20080214584-A1 | Method for treating cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-04 | — | — | US | disclosed |
| US-20080214584-A1 | Method for treating cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-04 | — | — | US | disclosed |
| WO-2008044782-A2 | COMBINATION DRUG | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-04-17 | — | — | WO | disclosed |
| US-20070244132-A1 | Fused Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070244132-A1 | Fused Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-18 | — | — | US | disclosed |
| EP-1752457-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244132-A1 | Fused Heterocyclic Compound | NOX3, ERBB3, CBR3 | TTBK1 2736/4885TTBK2 2764/4885EGFR 68/4885 |
| US-20090029973-A1 | FUSED HETEROCYCLIC COMPOUND | NOX3, ERBB3, CBR3 | TTBK1 2736/4885TTBK2 2764/4885EGFR 68/4885 |
| US-20130190405-A1 | METHODS AND USE OF COMPOUNDS THAT BIND TO HER2/NEU RECEPTOR COMPLEX | ERBB2, EGFR, ERBB3 | TTBK1 578/4885TTBK2 201/4885EGFR 2/4885 |
| US-20080214584-A1 | Method for treating cancer | ERBB2, EGFR, ERBB3 | TTBK1 831/4885TTBK2 350/4885EGFR 2/4885 |
| US-20090018335-A1 | FUSED HETEROCYCLIC COMPOUND | NOX3, ERBB3, CBR3 | TTBK1 2736/4885TTBK2 2764/4885EGFR 68/4885 |
| US-20110003805-A1 | CONCOMITANT DRUG | ERBB2, MTOR, ERBB4 | TTBK1 840/4885TTBK2 642/4885EGFR 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.